|
ProBiotix Health PLC said on Monday it has partnered with Wellizen Australia Pty Ltd to create a new dietary supplement capsule product targeting cardiometabolic health. Wakefield, England-based life sciences firm ProBiotix said it will supply its patented probiotic strain LPLDL for local manufacturing of the new product Tri-Biotic Cardi-Flo. Cardi-Flo will be introduced under Sydney, Australia-based Wellizen’s Theronomic brand. ProBiotix said the commercial rollout will take place in October, with an initial launch in Singapore through Wellizen’s direct retail consumer e-commerce platform. This is to be followed by a late October direct-to-consumer launch in Australia. ProBiotix said they plan to have additional market entries across New Zealand, Southeast Asia and other Asian markets. ProBiotix Chief Executive Steen Andersen said: ‘The use of our clinically proven LPLDL by Wellizen to complement their existing Theronomic consumer product range, marks a significant step for ProBiotix. It further validates the increasing application of our innovative technology to target those suffering with high cholesterol, and we are very excited about its future sales potential. ‘High cholesterol affects an estimated 30-48% of adults in Southeast Asia, around 30% in Australia, and nearly one-third of adults across the Middle East, representing a major and fast-growing cardiometabolic health challenge globally.’ Shares in Aquis-listed ProBiotix were flat at 7.75 pence on Monday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
